2Seventy Bio

2Seventy Bio is one of the...

• Russell 3000.

2Seventy Bio is a company listed under the stock ticker TSVT (US).

View the org chart displaying its 18 main executives

Most searched biographies at 2Seventy Bio

• Nick Leschly, Chief Executive Officer and Director
• Marcela Maus, Director
• Sarah Glickman, Director

Popular executive movements at 2Seventy Bio

• Wei Lin has joined the company as Director  (posted on March 8 2023).
• Kevin Chin, Head of Clinical Development, has left the company  (posted on March 2 2023).

Create your alert
to follow the executive moves at 2Seventy Bio.

2Seventy Bio has 2,145 competitors including Neptune Wellness Solutions (Canada), Eurofins (Luxembourg) and Biogen (United States (USA)).

Popular M&A news in Biotechnology

• Mediar Therapeutics has just announced a $85 Million fundraising (posted on March 17 2023).
• Switch Therapeutics has just announced a $52 Million fundraising (posted on March 17 2023).
• Sanofi has announced the acquisition of Provention Bio  (posted on March 15 2023).

Popular contacts in Biotechnology

• Neal Mohan - Director at 23andMe
• Marc Dunoyer - Independent Director at Orchard Therapeutics
• Katrin Turvey - Vice President and Head of Food & Beverage Key Account & Engineering at Kersia

Learn more about the Biotechnology industry >

Press releases by 2Seventy Bio

• 2seventy bio to Participate in Upcoming Investor Conferences | 2seventy Bio
• News Releases | 2seventy Bio
• 2seventy bio to Participate in Upcoming Investor Conferences | 2seventy Bio
• 2seventy bio to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference | 2seventy Bio
• 2seventy bio to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference | 2seventy Bio
• 2seventy bio Reports First Quarter Financial Results and Recent Operational Progress | 2seventy Bio
• 2seventy bio Reports First Quarter Financial Results and Recent Operational Progress | 2seventy Bio
• 2seventy bio Presents New Preclinical Data on bbT369, an Investigational Dual-Targeting Gene-Edited CAR T Cell Therapy, at the AACR Annual Meeting | 2seventy Bio
• 2seventy bio Presents New Preclinical Data on bbT369, an Investigational Dual-Targeting Gene-Edited CAR T Cell Therapy, at the AACR Annual Meeting | 2seventy Bio
• 2seventy bio to Participate in CG Horizons in Oncology Virtual Conference | 2seventy Bio
• View more press releases Close

Social media about 2Seventy Bio

• 2Seventy Bio on Wikipedia, Google News & Yahoo Finance
• 2Seventy Bio on LinkedIn, Twitter & YouTube

Contact by email its executives including Sarah Glickman

Call 2Seventy Bio at +1 339...

View the org chart

Register to receive your alert

Report an error